Showing results (51-60 of 57) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.Nature Communications|May 12, 2023
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy responseMeghana Pagadala, Timothy J Sears, Victoria H Wu, et al.Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.Medrxiv : the Preprint Server for Health Sciences|August 16, 2024
Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockadeIan T Mathews, Priyanka Saminathan, Mir Henglin, et al.Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.Pageof 6